In phase III ImPassion130 trial, the addition of immunotherapy to chemotherapy improved overall survival in metastatic triple-negative breast cancer patients. This benefit was significant only in patients harboring PD-L1-positive tumors, suggesting that stratification according to response biomarkers is needed to achieve consistent responses. Besides PD-L1 expression, a variety of potential biomarkers are under investigation for predicting immunotherapy efficacy in breast cancer, such as tumor-infiltrating lymphocytes, gene signatures, tumor mutational burden, microsatellite instability, and gut microbiome. Enriching future trials through these biomarkers could help identifying the population of responders, realizing what has been called precision immunotherapy.
Defining the immunogram of breast cancer: a focus on clinical trials / P. Tarantino, G. Curigliano. - In: EXPERT OPINION ON BIOLOGICAL THERAPY. - ISSN 1471-2598. - 19:5(2019), pp. 383-385. [10.1080/14712598.2019.1598372]
Defining the immunogram of breast cancer: a focus on clinical trials
G. Curigliano
2019
Abstract
In phase III ImPassion130 trial, the addition of immunotherapy to chemotherapy improved overall survival in metastatic triple-negative breast cancer patients. This benefit was significant only in patients harboring PD-L1-positive tumors, suggesting that stratification according to response biomarkers is needed to achieve consistent responses. Besides PD-L1 expression, a variety of potential biomarkers are under investigation for predicting immunotherapy efficacy in breast cancer, such as tumor-infiltrating lymphocytes, gene signatures, tumor mutational burden, microsatellite instability, and gut microbiome. Enriching future trials through these biomarkers could help identifying the population of responders, realizing what has been called precision immunotherapy.File | Dimensione | Formato | |
---|---|---|---|
Defining the immunogram of breast cancer a focus on clinical trials.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
644.83 kB
Formato
Adobe PDF
|
644.83 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.